Literature DB >> 19805105

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.

Diana Mandelker1, Sandra B Gabelli, Oleg Schmidt-Kittler, Jiuxiang Zhu, Ian Cheong, Chuan-Hsiang Huang, Kenneth W Kinzler, Bert Vogelstein, L Mario Amzel.   

Abstract

Mutations in oncogenes often promote tumorigenesis by changing the conformation of the encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which encodes p110alpha, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kalpha), is one of the two most frequently mutated oncogenes in human cancers. We report the structure of the most common mutant of p110alpha in complex with two interacting domains of its regulatory partner (p85alpha), both free and bound to an inhibitor (wortmannin). The N-terminal SH2 (nSH2) domain of p85alpha is shown to form a scaffold for the entire enzyme complex, strategically positioned to communicate extrinsic signals from phosphopeptides to three distinct regions of p110alpha. Moreover, we found that Arg-1047 points toward the cell membrane, perpendicular to the orientation of His-1047 in the WT enzyme. Surprisingly, two loops of the kinase domain that contact the cell membrane shift conformation in the oncogenic mutant. Biochemical assays revealed that the enzymatic activity of the p110alpha His1047Arg mutant is differentially regulated by lipid membrane composition. These structural and biochemical data suggest a previously undescribed mechanism for mutational activation of a kinase that involves perturbation of its interaction with the cellular membrane.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805105      PMCID: PMC2761334          DOI: 10.1073/pnas.0908444106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Improved expression of kinases in Baculovirus-infected insect cells upon addition of specific kinase inhibitors to the culture helpful for structural studies.

Authors:  André Strauss; Gabriele Fendrich; Michel André Horisberger; Janis Liebetanz; Bernd Meyhack; Jean-Marc Schlaeppi; Rita Schmitz
Journal:  Protein Expr Purif       Date:  2007-07-10       Impact factor: 1.650

3.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

4.  Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes.

Authors:  R T Nolte; M J Eck; J Schlessinger; S E Shoelson; S C Harrison
Journal:  Nat Struct Biol       Date:  1996-04

Review 5.  The PI3K-PDK1 connection: more than just a road to PKB.

Authors:  B Vanhaesebroeck; D R Alessi
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

6.  Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Authors:  Jeffrey D Carson; Glenn Van Aller; Ruth Lehr; Robert H Sinnamon; Robert B Kirkpatrick; Kurt R Auger; Dashyant Dhanak; Robert A Copeland; Richard R Gontarek; Peter J Tummino; Lusong Luo
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

7.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Authors:  Nathan T Ihle; Ryan Williams; Sherry Chow; Wade Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

8.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

9.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

Authors:  A Arcaro; M P Wymann
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

10.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

View more
  135 in total

1.  Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity.

Authors:  Jinan Wang; Fangfang Wang; Zhengtao Xiao; Guowen Sheng; Yan Li; Yonghua Wang
Journal:  J Mol Model       Date:  2011-12-03       Impact factor: 1.810

2.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

3.  Activation of PI3K signaling in Merkel cell carcinoma.

Authors:  Valentina Nardi; Youngchul Song; Juan A Santamaria-Barria; Arjola K Cosper; Quynh Lam; Anthony C Faber; Genevieve M Boland; Beow Y Yeap; Kristin Bergethon; Vanessa L Scialabba; Hensin Tsao; Jeffrey Settleman; David P Ryan; Darrell R Borger; Atul K Bhan; Mai P Hoang; Anthony J Iafrate; James C Cusack; Jeffrey A Engelman; Dora Dias-Santagata
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

Review 4.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 5.  Targeting Signaling Transduction Pathways in Bladder Cancer.

Authors:  Phillip H Abbosh; David J McConkey; Elizabeth R Plimack
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 6.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

Review 7.  Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Authors:  Sandra B Gabelli; Krisna C Duong-Ly; Evan T Brower; L Mario Amzel
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 8.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

9.  Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-α-positive Breast Cancer.

Authors:  Juan-Cheng Yang; Yang-Chang Wu; Yun-Hao Dai; Guan-Yu Chen; Chih-Hsin Tang; Wei-Chien Huang
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.